|
|||||
|
|
A Randomized Study of the Relative Pharmacokinetics,Pharmacodynamics, and Safety of Alirocumab,a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects |
|
| Authors: | Catherine Lunven Tobias Paehler Franck Poitiers Aurélie Brunet Jacques Rey Corinne Hanotin William J. Sasiela |
| Affiliation: | 1. Sanofi, , Paris, France;2. Sanofi, , Frankfurt, Germany;3. Sanofi, , Montpellier, France;4. Regeneron Pharmaceuticals, Inc., , Tarrytown, NY, USA |
| Abstract: | |
| Keywords: | Alirocumab Cholesterol Low‐density lipoprotein Pharmacodynamics Pharmacokinetics Proprotein convertase subtilisin/kexin type 9 |